Published in Mol Ther on July 23, 2014
Insight to drug delivery aspects for colorectal cancer. World J Gastroenterol (2016) 0.86
Antibody fragments as nanoparticle targeting ligands: a step in the right direction. Chem Sci (2016) 0.75
The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol (2008) 20.89
The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer (2002) 14.94
Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer (2006) 9.15
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci (2006) 4.67
Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep (2006) 4.15
Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med (2002) 3.54
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 2.88
Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc (2012) 2.55
Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn (2009) 2.35
PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release (2001) 2.15
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene (2002) 1.97
PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett (2012) 1.77
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene (2012) 1.75
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene (2000) 1.69
Expression, purification and use of recombinant annexin V for the detection of apoptotic cells. Nat Protoc (2009) 1.36
Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine (2007) 1.28
Targeting c-FLIP in cancer. Cancer Lett (2010) 1.25
c-FLIP, a master anti-apoptotic regulator. Exp Oncol (2012) 1.24
The active caspase-8 heterotetramer is formed at the CD95 DISC. Cell Death Differ (2003) 1.23
Death-receptor activation halts clathrin-dependent endocytosis. Proc Natl Acad Sci U S A (2006) 1.18
Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci U S A (2003) 1.16
Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res (2010) 1.14
Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement. Proc Natl Acad Sci U S A (2012) 1.11
Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett (2012) 1.10
Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Mol Cancer Ther (2008) 1.10
Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf B Biointerfaces (2012) 1.09
Antibody-drug conjugates. Nat Rev Drug Discov (2013) 1.08
Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. Bioconjug Chem (2008) 1.07
The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res (2013) 1.06
Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther (2010) 1.06
X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise. Clin Cancer Res (2010) 1.06
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Ann Oncol (2013) 1.04
Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells. Oncogene (2008) 1.03
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs (2013) 1.02
Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin Cancer Res (2010) 0.99
CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. J Immunol (2010) 0.98
Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. Eur J Cancer (2011) 0.98
Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy. Clin Cancer Res (2012) 0.96
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized. J Biol Chem (2012) 0.93
c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome. Br J Haematol (2005) 0.92
Targeting TRAIL death receptors. Curr Opin Pharmacol (2008) 0.92
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. Cancer (2013) 0.87
The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium. Clin Cancer Res (1998) 0.85
Enhanced antitumor activity of the photosensitizer meso-Tetra(N-methyl-4-pyridyl) porphine tetra tosylate through encapsulation in antibody-targeted chitosan/alginate nanoparticles. Biomacromolecules (2013) 0.84
The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms. Apoptosis (2013) 0.84
SnapShot: Extrinsic apoptosis pathways. Cell (2010) 0.82
Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery. Biomaterials (2011) 0.81
Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy. Cancer Immunol Res (2016) 0.78
USP17 is required for clathrin mediated endocytosis of epidermal growth factor receptor. Oncotarget (2014) 0.77
The development of sustained release drug delivery platforms using melt-extruded cellulose-based polymer blends. J Pharm Pharmacol (2016) 0.75
The SCF ubiquitin ligase complex modulates TRAIL-R2-induced apoptosis by regulating FLIP(L). Cell Death Differ (2020) 0.75
FLIP: A Targetable Mediator of Resistance to Radiation in Non-Small Cell Lung Cancer. Mol Cancer Ther (2016) 0.75